Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 90

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 90
---
 and artificial intelligence capabilities, as well as its hybrid business -to-business(B2B) and business -to-business-to-consumer(B2B2C) distribution strategies. The Company’s intellectual property portfolio and valuation, considered attractive relative to global public and private comparable companies in the genomics, diagnostics, and healthcare technology sectors, further supported the APx Board’s determination. 11 The APx Board reviewed financial metrics, including revenue and EBITDA comparisons, but due to the emerging nature of the industries in which the Company operates, placed greater emphasis on qualitative factors like the total addressable market, scalability, and operational efficiencies. The APx Board also relied on results from due diligence that assessed the Company’s material contracts, corporate governance, regulatory compliance, financial history, and market opportunities, including potential expansion within Latin America. While acknowledging risks such as the lack of a third -partyfairness opinion and challenges in transitioning to a public company, the Board determined, based on its collective experience and judgment, that the potential strategic and financial benefits to APx and its shareholders outweighed these risks, leading to its unanimous approval of the Business Combination Agreement. See the section entitled “ APx Board of Directors’ Reasons for the Approval of the Business Combination” for more information. Risk Factors In evaluating the proposals to be presented at the Special Meeting, a shareholder should carefully read this proxy statement/prospectus and especially consider the factors discussed in the section entitled “ Risk Factors.” Further, the Company has historically incurred significant losses: $1,322,306, $4,516,095 and $1,291,932 for the six months ended December31, 2024, and for the fiscal years ended June 30, 2024 and 2023, respectively. The Company has also recorded accumulated deficits of $8,263,789, $6,941,483 and $3,588,427 as of December31, 2024, June 30, 2024 and 2023, respectively. Additionally, the Company’s recurring cash outflows from operations amounted to $1,022,381, $1,885,895 and $1,306,705 for the six months ended December31, 2024 and for the years ended June 30, 2024 and 2023. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as we continue to expand research and development efforts, enhance our existing consumer products, services and business model, broaden its customer base, work with